Scientists at The University of Nottingham have isolated three important genes involved in the development of a type of childhood brain cancer. The breakthrough is revealed in a study published in the British Journal of Cancer. Read more ...
New research has highlighted stark disparities in access to the latest cancer drugs across European Union nations, according to data presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm. While countries like France, Spain, Austria and Switzerland have tended to introduce the new drugs quickly, researchers say, others such as the UK and more recent EU entrants bring them in more slowly. Read more ...
An investigational drug that combats ovarian cancer by inhibiting the formation of new blood vessels has shown promise in a phase II trial, according to a presentation at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm. Prof. Michael Friedlander from Australia presented the results of an international collaborative trial which administered the drug to 35 patients with recurrent ovarian, fallopian tube or peritoneal carcinoma. Read more ...
Physicians now have a powerful new tool with industry-leading technology to ablate soft tissue. The Interventional Oncology business unit of Covidien Ltd. (NYSE: COV, BSX: COV), the world leader in advanced energy-based surgical systems, today announced the global release of the Evident™ microwave ablation system. The Evident™ microwave ablation system is intended for coagulation of soft tissue during percutaneous, laparoscopic and open surgical procedures. Read more ...
For patients with chemotherapy-induced anemia, adding intravenous iron to treatment with the drug darbepoetin alfa results in a faster and more potent improvement in response with lower doses of the drug, according to data presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm. Anemia is a common problem in cancer patients, caused by a combination of factors including the malignancy itself, plus the effects of chemotherapy. Read more ...
The investigational agent ipilimumab is showing promise as a therapy for both treatment-naïve and previously treated patients with late-stage melanoma, according to phase 2 results released here at the 33rd Congress of the European Society for Medical Oncology (ESMO). Read more ...
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the malignant melanoma drug market, driven by the launch of emerging agents, will experience robust annual 12 percent growth through 2012 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Read more ...
Drais Pharmaceuticals, Inc. and Unibioscreen S.A. announced that they have entered into a global agreement to develop and commercialize UNBS5162, one of Unibioscreen's investigational drug and potential breakthrough treatments for cancer. UNBS5162 was discovered by Unibioscreen and is currently in Phase I trials in the United States in cancer patients with advanced solid tumors or lymphoma. Read more ...
Tuesday, September 16, 2008
Treating Recurring Cold Sores
Suffering from chronic cold sores is a very annoying and embarrassing problem. It is caused by Herpes Simplex Virus Type 1 (HSV-1) and the virus is highly contagious. People will avoid you and it can ruin your social and personal life. A close contact with someone through kissing and oral sex can cause the virus to spread from one person to another. Once you have the virus, it could become a chronic problem and it is important to know the effective ways on treating recurring cold sores.
Subscribe to:
Posts (Atom)
